Why the study?
Does enteric coating or dose reduction of aspirin minimize gastric mucosal injury in healthy volunteers?
Population
12 healthy volunteers
Comparison
Enteric-coated aspirin 300 mg, plain aspirin 75… vs Placebo (five daily doses)
Design
Other, blinded conditions
Follow-up
5 days per treatment period
Authors
Loading...
Enteric coating may limit short-term aspirin erosions in volunteers; leaves open clinical GI outcomes in patients.
Does enteric coating or dose reduction of aspirin minimize gastric mucosal injury in healthy volunteers?
Enteric-coated aspirin 300 mg reduces acute gastric mucosal injury to placebo levels compared to plain aspirin, suggesting it is an effective strategy to prevent aspirin-induced gastric damage.
Colé et al. (1999) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: